Amarin Corp Plcuk (AMRN) Enterprise Value (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Enterprise Value of -$314.7 million for Q2 2026, down 5.35% year-over-year from -$332.5 million in Q2 2025, and down 2.21% quarter-over-quarter from -$307.9 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Enterprise Value (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Enterprise Value for 17 consecutive years, with -$314.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 5.35% year-over-year to -$314.7 million; the TTM figure through Jun 2026 stood at -$314.7 million (down 5.35% YoY), while the FY2025 annual figure was -$302.6 million, down 2.84% from the prior year.
- Enterprise Value fell to -$314.7 million in Q2 2026 per AMRN's latest filing, from -$307.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$281.8 million in Q1 2025 and bottomed at -$362.6 million in Q1 2022.
- Historically, Enterprise Value has averaged -$308.6 million across 5 years, with a median of -$307.3 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 38.45% — and 2026, when it fell 9.25%.
- Amarin Corp Plc\Uk's Enterprise Value stood at -$309.4 million in 2022, then fell by 3.65% to -$320.7 million in 2023, then gained by 8.25% to -$294.2 million in 2024, then fell by 2.84% to -$302.6 million in 2025, then fell by 4.0% to -$314.7 million in 2026.
- Business Quant data shows AMRN's Enterprise Value at -$314.7 million in Q2 2026, -$307.9 million in Q1 2026, and -$302.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.98 Bn | 627.22 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 466.45 Bn | 459.88 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 372.04 Bn | 364.90 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 299.31 Bn | 291.62 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 256.25 Bn | 251.35 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 235.50 Bn | 221.52 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.26 Bn | 147.56 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 104.79 Bn | 100.62 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Amarin Corp Plcuk | 5.88 Bn | 5.57 Bn | 14.99 Mn | -314.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -314.70 Mn |
| Mar 31, 2026 | -307.90 Mn |
| Dec 31, 2025 | -302.59 Mn |
| Sep 30, 2025 | -286.60 Mn |
| Jun 30, 2025 | -298.73 Mn |
| Mar 31, 2025 | -281.82 Mn |
| Dec 31, 2024 | -294.22 Mn |
| Sep 30, 2024 | -305.74 Mn |
| Jun 30, 2024 | -306.66 Mn |
| Mar 31, 2024 | -308.18 Mn |
| Dec 31, 2023 | -320.66 Mn |
| Sep 30, 2023 | -320.66 Mn |
| Jun 30, 2023 | -312.92 Mn |
| Mar 31, 2023 | -304.41 Mn |
| Dec 31, 2022 | -309.36 Mn |
| Sep 30, 2022 | -303.70 Mn |
| Jun 30, 2022 | -313.23 Mn |
| Mar 31, 2022 | -362.61 Mn |
| Dec 31, 2021 | -454.13 Mn |
| Sep 30, 2021 | -479.20 Mn |